Common toxicities of mammalian target of rapamycin inhibitors

Area of Science:

• Oncology
• Pharmacology
• Toxicology

Background:

• Targeted therapies, including mammalian target of rapamycin (mTOR) inhibitors, represent a significant advancement in cancer treatment.
• The toxicities associated with mTOR inhibitors differ from traditional chemotherapy agents and share some similarities with transplant drug toxicities.
• Understanding these unique side effects is crucial for effective patient management.

Purpose of the Study:

• To review and summarize the common toxicities associated with mammalian target of rapamycin (mTOR) inhibitors used in oncology.
• To differentiate the side effect profiles of mTOR inhibitors from conventional chemotherapy.
• To highlight the importance of monitoring for both mild and severe adverse events.

Main Methods:

• Literature review of studies on mammalian target of rapamycin (mTOR) inhibitors and their associated toxicities.
• Analysis of reported side effects, focusing on common and unique adverse events.
• Categorization of toxicities into dermatologic, mucosal, and metabolic adverse events.

Main Results:

• Mucositis and rash are frequently observed side effects of mTOR inhibitors.
• Metabolic toxicities, including hyperglycemia, hyperlipidemia, and hypophosphatemia, are characteristic of this drug class.
• While often mild, some toxicities can be severe, necessitating vigilant patient monitoring.

Conclusions:

• Mammalian target of rapamycin (mTOR) inhibitors present a distinct toxicity profile compared to traditional chemotherapy.
• Routine monitoring for mucositis, rash, and metabolic disturbances is essential for patients receiving mTOR inhibitors.
• Awareness of these specific toxicities aids in optimizing cancer treatment strategies and patient care.